Fluconazole-Resistant Candida: Mechanisms and Risk Factor Identification

Recently published papers of interest have been highlighted as: • Of importance •• Of major importance

1. 1.
   Charlier C, Hart E, et al. Fluconazole for the management of invasive candidiasis: where do we stand after 15 years? J Antimicrob Chemother 2006. 57(3): 384–410.CrossRefPubMedGoogle Scholar
2. 2.
   Löffler J, Kelly SL, Hebert H, Schumacher U, Lass-Flörl C & Einsele H. Molecular analysis of cyp51 from fluconazole-resistant Candida albicans strains. FEMS Microbiol Lett 1997;151:263–8.CrossRefPubMedGoogle Scholar
3. 3.
   Orozco AS, Higginbotham LM, Hitchcock CA, et al. Mechanism of fluconazole resistance in Candida krusei. Antimicrob Agents Chemother 1998;42:2645–9.PubMedGoogle Scholar
4. 4.
   Franz R, Kelly SL, Lamb DC, Kelly DE, Ruhnke M & Morschhäuser J. Multiple molecular mechanisms contribute to a stepwise development of fluconazole resistance in clinical Candida albicans strains. Antimicrob Agents Chemother 1998;42:3065–72.PubMedGoogle Scholar
5. 5.
   Lopez-Ribot JL, McAtee RK, Lee LN, et al. Distinct patterns of gene expression associated with development of fluconazole resistance in serial Candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis. Antimicrob Agents Chemother 1998;42:2932–7.PubMedGoogle Scholar
6. 6.
   Henry KW, Nickels JT, Edlind TD. Upregulation of ERG genes in Candida species by azoles and other sterol biosynthesis inhibitors. Antimicrob Agents Chemother 2000;44:2693–700.CrossRefPubMedGoogle Scholar
7. 7.
   Parkinson T, Falconer DJ, Hitchcock CA. Fluconazole resistance due to energy-dependent drug efflux in Candida glabrata. Antimicrob Agents Chemother 1995;39:1696–9.PubMedGoogle Scholar
8. 8.
   Albertson GD, Niimi M, Cannon RD, Jenkinson HF. Multiple efflux mechanisms are involved in Candida albicans fluconazole resistance. Antimicrob Agents Chemother 1996;40:2835–41.PubMedGoogle Scholar
9. 9.
   Pfaller, M. A., D. J. Diekema, et al. “Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing.” Clin Microbiol Rev 2006, 19(2): 435–447.CrossRefPubMedGoogle Scholar
10. 10.
    Sanglard D, Kuchler K, Ischer F, Pagani JL, Monod M & Bille J. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob Agents Chemother 1995;39:2378–86.PubMedGoogle Scholar
11. 11.
    White TC. Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob Agents Chemother 1997;41:1482–7.PubMedGoogle Scholar
12. 12.
    White TC, Marr KA, Bowden RA. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev 1998;11:382–402.PubMedGoogle Scholar
13. 13.
    • Kanafani ZA, Perfect JR. Antimicrobial resistance: resistance to antifungal agents: mechanisms and clinical impact. Clin Infect Dis 2008;46:120–8. This article presents an excellent summary of mechanisms of resistance to antifungal agents (azole, polyene, echinocandin, and flucytosine) and its impact on clinical outcomes. CrossRefPubMedGoogle Scholar
14. 14.
    Nailis H, Vandenbosch D, Deforce D, Nelis HJ, Coenye T. Transcriptional response to fluconazole and amphotericin B in Candida albicans biofilms. Res Microbiol 2010;161:284–92.CrossRefPubMedGoogle Scholar
15. 15.
    Reboutier D, Piednoël M, Boisnard S, et al. Combination of different molecular mechanisms leading to fluconazole resistance in a Candida lusitaniae clinical isolate. Diagn Microbiol Infect Dis 2009;63:188–93.CrossRefPubMedGoogle Scholar
16. 16.
    Chen CG, Yang YL, Tseng KY, et al. Rep1p negatively regulating MDR1 efflux pump involved in drug resistance in Candida albicans. Fungal Genet Biol 2009;46:714–20.CrossRefPubMedGoogle Scholar
17. 17.
    Marichal P, Koymans L, Willemsens S, et al. Contribution of mutations in the cytochrome P450 14alpha-demethylase (Erg11p, Cyp51p) to azole resistance in Candida albicans. Microbiology 1999;145 ( Pt 10):2701–13.PubMedGoogle Scholar
18. 18.
    Sanglard, D., K. Kuchler, et al. “Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters.” Antimicrob Agents Chemother 1995, 39(11): 2378–2386.PubMedGoogle Scholar
19. 19.
    •• Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009, 48(5): 503–535. This is the most recent update of the IDSA guidelines. It addresses the use of the different antifungals in the management of Candida infections, considering the emergence of fluconazole resistance. CrossRefPubMedGoogle Scholar
20. 20.
    National Committee for Clinical Laboratory Standards. 2002. Reference method for broth microdilution antifungal susceptibility testing of yeasts: approved standard, 2nd ed, M27-A2. National Committee for Clinical Laboratory Standards, Wayne, PA.Google Scholar
21. 21.
    Wang H, Kong F, Sorrell TC, et al. Rapid detection of ERG11 gene mutations in clinical Candida albicans isolates with reduced susceptibility to fluconazole by rolling circle amplification and DNA sequencing. BMC Microbiol 2009;9:167.CrossRefPubMedGoogle Scholar
22. 22.
    Guinea J, Recio S, Escribano P, et al. Rapid antifungal susceptibility determination for yeast isolates by use of Etest performed directly on blood samples from patients with fungemia. J Clin Microbiol 2010;48:2205–12.CrossRefPubMedGoogle Scholar
23. 23.
    Alexander BD, Byrne TC, Smith KL, et al. Comparative evaluation of Etest and Sensititre YeastOne panels against the Clinical and Laboratory Standards Institute M27-A2 reference broth microdilution method for testing Candida susceptibility to seven antifungal agents. J Clin Microbiol 2007;45:698–706.CrossRefPubMedGoogle Scholar
24. 24.
    Nett JE, Sanchez H, Cain MT & Andes DR. Genetic basis of Candida biofilm resistance due to drug-sequestering matrix glucan. J Infect Dis 2010;202:171–5.CrossRefPubMedGoogle Scholar
25. 25.
    Faiz, S., B. Neale, et al. Risk-based fluconazole prophylaxis of Candida bloodstream infection in a medical intensive care unit. Eur J Clin Microbiol Infect Dis 2009, 28(6): 689–69.CrossRefPubMedGoogle Scholar
26. 26.
    Brion LP, Uko SE, et al. Risk of resistance associated with fluconazole prophylaxis: systematic review. J Infect 2007, 54(6): 521–529.CrossRefPubMedGoogle Scholar
27. 27.
    • Garnacho-Montero J, Diaz-Martin A, et al. Risk factors for fluconazole-resistant candidemia. Antimicrob Agents Chemother 2010, 54(8): 3149–3154. This is a well-done prospective study evaluating the risk factors associated with fluconazole-resistant candidemia in Spain. CrossRefPubMedGoogle Scholar
28. 28.
    Slavin MA, Sorrell TC, et al. Candidaemia in adult cancer patients: risks for fluconazole-resistant isolates and death. J Antimicrob Chemother 2010, 65(5): 1042–1051.CrossRefPubMedGoogle Scholar
29. 29.
    Hebert C, Villaran R, et al. Prior antimicrobial exposure and the risk for bloodstream infection with fluconazole-non-susceptible Candida strains. Scand J Infect Dis 2010, 42(6–7): 506–509.CrossRefPubMedGoogle Scholar
30. 30.
    Pultz NJ, Stiefel U, et al. Effect of parenteral antibiotic administration on establishment of intestinal colonization by Candida glabrata in adult mice. Antimicrob Agents Chemother 2005, 49(1): 438–440.CrossRefPubMedGoogle Scholar
31. 31.
    Lee I, Fishman NO, et al. Risk factors for fluconazole-resistant Candida glabrata bloodstream infections. Arch Intern Med 2009, 169(4): 379–383.CrossRefPubMedGoogle Scholar